Nebenwirkungen · Braftovi
Braftovi 50 mg hard capsules Braftovi 75 mg hard capsules · Abschnitt 4.8 · PDF-Seite 13
HOS-140071 · Präparat HOS-098444
The safety of encorafenib (300 mg orally once daily) in combination with cetuximab (dosed as per its SmPC) was evaluated in 216 patients with BRAF V600E-mutant metastatic colorectal cancer, based on the phase III study ARRAY-818-302. The most common ADRs (>25%) reported in this population were: fatigue, nausea, diarrhoea, dermatitis acneiform, abdominal pain, arthralgia/musculoskeletal pain, decreased appetite, rash and vomiting. The rate of all study drug discontinuation due to any adverse reaction was 1.9 % in patients treated with encorafenib 300 mg in combination with cetuximab.
Originalpassage; keine automatisch abgeleitete Schwere, Häufigkeit oder Kausalität. Auch verneinte Befunde und nicht untersuchte Kombinationen bleiben sichtbar.
Vollständigen Kontext in der EMA-Fachinformation lesen →Quellennachweis
Version 2026-07-01T15:53:00Z · SHA-256 47125c84bb304df39202c4dc14aefc287bbf903ef279d3e55fe42dc6648e375c · Passage cd16307b7b7c88ceeb924c3d3b88453380b50847bde572c8ed0079dc84bb9821 · Zeichen 1951–2540 im Abschnitt